VitriVax

VitriVax is a private, pre-clinical stage biotech company founded in 2019, specializing in advanced drug delivery systems for vaccines. Its core technology, the Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform, is designed to produce vaccines that are both thermostable (not requiring cold chain) and capable of single-shot administration through timed release. The company is led by a seasoned team of scientists and entrepreneurs and is backed by investors including Piedmont Capital Partners and Adjuvant Capital. VitriVax's approach targets a significant unmet need in global health by aiming to improve vaccination rates in remote and resource-limited settings.

Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform, combining spray-dry encapsulation in a sugar glass matrix for thermostability with atomic layer deposition (ALD) of metal oxides for controlled, timed release of antigens/adjuvants to enable single-dose vaccination.

VitriVax competes in the vaccine formulation and drug delivery space, where numerous entities are developing thermostable platforms (e.g., using lyophilization, novel stabilizers) and sustained-release technologies (e.g., microparticles, implants). Its specific combination of spray-drying and ALD for timed release appears to be a differentiating approach.